NTLA Intellia Therapeutics, Inc. - Common Stock
Intellia Therapeutics, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
और पढ़ें
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, (with colleagues at University of California, Berkeley) and Virginijus Šikšnys (with colleagues at Vilnius University). The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Lonvo-z is an investigational CRISPR therapy candidate for the treatment of hereditary angioedema (HAE) currently in Phase 3 studies.
Intellia's proprietary non-viral gene knock out platform deploys lipid nanoparticles to deliver to the liver a two-part genome editing system: guide RNA specific to the disease-causing gene and messenger RNA that encodes the Cas9 enzyme, which carries out the precision editing.
Intellia also has a number of research programs for in vivo and ex vivo therapeutic candidates with potential applications in diseases including cancer, alpha-1 antitrypsin deficiency, and hemophilia. The company is also working on a variety of additional gene editing technologies including base editing and DNA writing.
History
Intellia Therapeutics was founded in November 2014 to develop biopharmaceuticals using CRISPR.
It was backed by Atlas Venture and Novartis; the founding CEO was Nessan Bermingham from Atlas and the founding CSO was John Leonard, formerly CSO of AbbVie. The academic scientists involved in the founding included Rodolphe Barrangou, Rachel Haurwitz, Luciano Marraffini, Erik Sontheimer, and Derrick Rossi. The intellectual property around CRISPR was contested from the beginning; Intellia in-licensed patents from Caribou Biosciences, which had licensed patents from University of California invented by Jennifer Doudna.
Novartis had funded the Series A round because of its interest in applying CRISPR in CAR-T, and in January 2015 Novartis and Intellia reached a deal through which Novartis obtained rights to use CRISPR for its CAR-T program, and the companies agreed to collaborate on ways to use CRISPR to treat diseases involving hematopoietic stem cells including beta thalassemia and sickle cell disease. Intellia formed a division called eXtellia Therapeutics to manage the CAR-T collaboration with Novartis.
In December 2016, the company moved to its new 80,000 sq. ft. laboratory and office space in Cambridge, Massachusetts. By that time, it had obtained a license for another company's a lipid nanoparticle drug delivery system to help with its efforts to deliver CRISPR drugs to the liver, without being degraded in the bloodstream; at that time it had not disclosed the licensor.
In March 2017, Intellia and Regeneron, partners in co-developing a CRISPR-based treatment for transthyretin amyloidosis, presented data from a gene editing experiment in mice. By that time, University of California had lost a challenge to Broad's CRISPR patents, putting Intellia at a disadvantage relative to Editas.
In April 2017, Intellia entered into a partnership with Regeneron Pharmaceuticals under which Regeneron gained the exclusive right to use Intellia's CRISPR platform on up to 10 drug targets, of which up to five could be outside of the liver, and the companies agreed to co-develop other targets. Regeneron paid $75 million upfront, as well as milestones and royalties. The company said it planned to put $10 million of the funds into its bioinformatics program, to help it evaluate targets.
In December 2017, John Leonard, who had experience in drug development, took over as CEO.
In October 2019, Intellia named Glenn Goddard as its executive vice president and CFO. Prior to Intellia, Goddard was the CFO at Generation Bio Company and senior vice president of finance at Agios Pharmaceuticals.
In October 2020, Jennifer Doudna, one of Intellia's scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9 genome editing technology. Doudna shared the award with her research collaborator, Emmanuelle Charpentier. This is the first time two women scientists have jointly won a Nobel Prize in Chemistry.
In June 2021, Intellia made history by announcing interim Phase 1 data for NTLA-2001, demonstrating the ability to precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. This was the first time any human clinical data has been published for an in vivo gene editing therapeutic candidate. The landmark data was published in the New England Journal of Medicine in August 2021.
In September and November 2022, Intellia presented the initial positive clinical data from their second in vivo CRISPR-candidate, NTLA-2002 demonstrating for the first time the potential clinical benefits of a CRISPR-based therapy with initial results now available beyond biomarker data. In January 2024, Intellia laid off 15% of its employees. A year later, Intellia announced a 27% net workforce reduction.
Funding
In November 2014, Intellia Therapeutics raised $15 million in Series A round. In September 2015, a Series B round secured $70 million. In May 2016, Intellia announced the closing of its initial public offering which raised approximately $112.1 million. In the course of going public, the company disclosed that it had licensed the lipid drug delivery system from Novartis, and that it involved creating lipid droplets to encapsulate the CRISPR agents.
== References ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
NTLA स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
NTLA स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
NTLA विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 4 16.7%
- खरीदें 9 37.5%
- होल्ड 8 33.3%
- बेचें 2 8.3%
- मजबूत बिक्री 1 4.2%
12-महीने का मूल्य लक्ष्य
17 विश्लेषक · 2026-08-13Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $-0.80 | $-0.82 | 0.02% |
| 31 मार्च 2026 | $-0.81 | $-0.93 | 0.12% |
| 31 दिसमबर 2025 | $-0.83 | $-0.97 | 0.14% |
| 30 सितमबर 2025 | $-0.92 | $-1.02 | 0.10% |
| 30 जून 2025 | $-0.98 | $-1.04 | 0.06% |
| 31 मार्च 2025 | $-1.10 | $-1.31 | 0.21% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| NTLA | $1.05B | -2.4 | 16.9% | -609.8% | -59.5% | — |
| DMRA | — | — | 38.3% | -17981.1% | -167.0% | — |
| SRPT | $2.26B | -3.0 | 15.6% | -32.5% | -57.1% | — |
| SNDX | $1.84B | -6.4 | 627.8% | -165.6% | -257.1% | — |
| ANAB | — | -105.4 | 157.0% | — | — | — |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | — |
| FBRX | $353M | -5.8 | 106.6% | -2555.2% | -86.9% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| BCAX | $953M | -6.7 | — | — | -33.0% | — |
| TYRA | $1.41B | -13.1 | — | — | -42.7% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M | |
| Cost of Revenue | · | · | · | · | $0 | $0 | $0 | $0 | · | · | |
| R&D Expense | $389M | $466M | $435M | $420M | $230M | $150M | $108M | $89M | $68M | $32M | |
| SG&A Expense | $120M | $126M | $116M | $90M | $71M | $44M | $41M | $32M | $28M | $17M | |
| Operating Expenses | $509M | $592M | $552M | $510M | $301M | $195M | $149M | $121M | $96M | $49M | |
| Operating Income | $-441M | $-534M | $-515M | $-458M | $-268M | $-137M | $-106M | $-91M | $-70M | $-32M | |
| Interest Income | $29M | $48M | $50M | $9M | $1M | $2M | $7M | $6M | $2M | $525.0K | |
| Other Non-op | $28M | $15M | $34M | $-16M | $-42.0K | $2M | $7M | · | · | · | |
| Pretax Income | · | · | · | · | · | · | · | · | $-68M | $-32M | |
| Income Tax | $0 | · | · | · | · | · | · | · | · | $0 | |
| Net Income | $-413M | $-519M | $-481M | $-474M | $-268M | $-134M | $-474M | $-85M | $-68M | $-32M | |
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | · | · | · | · | |
| EPS (Diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | · | · | · | · | |
| Shares (Basic) | 108,376,000 | 98,849,000 | 88,770,000 | 76,972,000 | 70,894,000 | 55,987,000 | · | · | · | · | |
| Shares (Diluted) | 108,376,000 | 98,849,000 | 88,770,000 | 76,972,000 | 70,894,000 | 55,987,000 | · | · | · | · | |
| EBITDA | $-431M | $-524M | $-506M | $-451M | $-261M | $-130M | $-101M | $-86M | · | $-32M |
बैलेंस शीट 22
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $189M | $227M | $524M | $123M | $160M | $57M | $59M | $341M | $273M | |
| Short-term Investments | $294M | $412M | $685M | $669M | $625M | $437M | $222M | $255M | · | · | |
| Receivables | $9M | $9M | $36M | $4M | $2M | $2M | $5M | $8M | $10M | $6M | |
| Prepaid Expense | $68M | $30M | $50M | $20M | $19M | $17M | $5M | $3M | $4M | $2M | |
| Current Assets | $528M | $640M | $998M | $1.22B | $769M | $617M | $289M | $325M | $355M | $281M | |
| PP&E (Net) | $18M | $27M | $33M | $28M | $21M | $16M | $18M | $17M | $15M | $11M | |
| PP&E (Gross) | $76M | $77M | $73M | $61M | $47M | $35M | $32M | $26M | $20M | $12M | |
| Accum. Depreciation | $59M | $50M | $40M | $33M | $26M | $19M | $14M | $9M | $4M | $1M | |
| Other Non-current Assets | · | · | · | · | · | $5M | $3M | $5M | $6M | $7M | |
| Total Assets | $842M | $1.19B | $1.30B | $1.52B | $1.29B | $676M | $334M | $347M | $376M | $299M | |
| Accounts Payable | $20M | $15M | $7M | $5M | $10M | $10M | $4M | $3M | $2M | $5M | |
| Accrued Liabilities | $50M | $55M | $67M | $61M | $43M | $26M | $13M | $11M | $8M | $6M | |
| Current Liabilities | $104M | $111M | $115M | $127M | $126M | $64M | $36M | $41M | $31M | $31M | |
| Capital Leases | $67M | $190M | $97M | $114M | $65M | $34M | $13M | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $0 | · | · | $13.0K | $168.0K | $293.0K | |
| Total Liabilities | $171M | $319M | $251M | $285M | · | · | · | · | · | · | |
| Common Stock | $12.0K | $10.0K | $9.0K | $9.0K | $7.0K | $7.0K | $5.0K | $5.0K | $4.0K | $4.0K | |
| Retained Earnings | $-2.59B | $-2.18B | $-1.66B | $-1.18B | $-703M | $-435M | $-301M | $-201M | $-121M | $-54M | |
| AOCI | $1M | $605.0K | $-2M | $-7M | $-3M | $1.0K | $261.0K | $-28.0K | · | · | |
| Stockholders' Equity | $671M | $872M | $1.05B | $1.24B | $1.04B | $527M | $270M | $278M | $301M | $210M | |
| Liabilities + Equity | $842M | $1.19B | $1.30B | $1.52B | $1.29B | $676M | $334M | $347M | $376M | $299M | |
| Shares Outstanding | 116,317,060 | 102,029,594 | 92,997,158 | 87,103,007 | 74,485,883 | 66,234,056 | 50,198,044 | 45,224,480 | 42,384,623 | 36,018,540 |
नकदी प्रवाह 11
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $10M | $9M | $8M | $7M | $6M | $6M | $4M | $3M | $1M | |
| Stock-based Comp | $80M | $154M | $134M | $91M | $47M | $20M | $15M | $17M | $15M | $7M | |
| Other Non-cash | $-72M | $6M | $-56M | $42M | $-11M | $58M | $-24M | $3M | · | · | |
| Operating Cash Flow | $-395M | $-349M | $-394M | $-333M | $-225M | $-50M | $-103M | $-61M | $-65M | $36M | |
| CapEx | $1M | $6M | $14M | $14M | $13M | $4M | $7M | $6M | $10M | $6M | |
| Investing Cash Flow | $228M | $126M | $-31M | $160M | $-551M | $-214M | $25M | $-261M | $-10M | $-6M | |
| Stock Issued | $128M | $177M | $120M | · | $1.82B | $1.12B | $72M | $29M | $141M | $171M | |
| Net Stock Activity | $128M | · | · | · | $1.82B | $1.12B | $72M | $29M | · | $171M | |
| Financing Cash Flow | $131M | $186M | $130M | $583M | $737M | $372M | $76M | $40M | $143M | $167M | |
| Net Change in Cash | $-35M | $-38M | $-295M | $410M | $-39M | $107M | $-2M | $-282M | $68M | $197M | |
| Free Cash Flow | $-396M | $-355M | $-408M | $-347M | $-238M | $-53M | $-110M | $-68M | · | $30M |
लाभप्रदता 6
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% | · | · | |
| Net Margin | -609.8% | -896.8% | -1326.5% | -909.8% | -810.5% | -231.5% | -230.9% | -280.4% | · | · | |
| EBITDA Margin | -637.2% | -905.3% | -1395.8% | -864.5% | -789.5% | -224.6% | -233.8% | -283.9% | · | · | |
| ROA | -40.6% | -41.7% | -34.1% | -33.7% | -27.2% | -26.6% | -29.2% | -23.6% | · | -16.6% | |
| ROE | -59.5% | -56.6% | -46.1% | -46.0% | -24.9% | -31.3% | -36.5% | -31.5% | · | -33.5% | |
| ROIC | · | · | · | · | · | · | · | · | · | -15.3% |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.1 | 5.8 | 8.7 | 9.6 | 6.1 | 9.6 | 8.1 | 8.0 | · | 9.2 | |
| Quick Ratio | 4.4 | 5.5 | 8.2 | 9.5 | 6.0 | 9.3 | 8.0 | 1.6 | · | 9.1 |
दक्षता 2
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | · | · | |
| Receivables Turnover | 7.5 | 6.7 | 1.7 | 13.4 | 14.6 | 34.7 | 10.5 | 3.4 | · | · |
विकास दरें 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 16.9% | 59.6% | -30.4% | 57.7% | -43.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 9.1% | 20.5% | -14.5% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $68M | $58M | $36M | $52M | $33M | $58M | $43M | $30M | $26M | $16M | |
| Net Income TTM | $-413M | $-519M | $-481M | $-474M | $-268M | $-134M | $-474M | $-85M | $-68M | $-32M | |
| Market Cap | $1.05B | $1.19B | $2.84B | $3.04B | $8.81B | $2.73B | $736M | $617M | · | $472M | |
| P/E | -2.4 | -2.2 | -5.6 | -5.7 | -31.3 | -22.7 | · | · | · | · | |
| P/S | 15.5 | 20.6 | 78.2 | 58.3 | 266.5 | 47.1 | 17.1 | 20.3 | · | 28.7 | |
| P/B | 1.6 | 1.4 | 2.7 | 2.5 | 8.5 | 5.2 | 2.7 | 2.2 | · | 2.3 | |
| P / Tangible Book | 1.6 | 1.4 | 2.7 | 2.5 | 8.5 | 5.2 | · | · | · | · | |
| P / Cash Flow | -2.6 | -3.4 | -7.2 | -9.1 | -39.1 | -54.7 | -7.1 | -10.1 | · | 13.1 | |
| P / FCF | -2.6 | -3.4 | -6.9 | -8.8 | -37.0 | -51.0 | -6.7 | -9.1 | · | 15.8 | |
| Earnings Yield | -42.4% | -45.0% | -17.8% | -17.7% | -3.2% | -4.4% | · | · | · | · |
आय विवरण 13
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $15M | $23M | $14M | $14M | $17M | $13M | $9M | $7M | $29M | $-2M | $12M | $14M | $13M | $14M | $13M | |
| R&D Expense | $83M | $81M | $89M | $95M | $97M | $108M | $117M | $123M | $114M | $112M | $109M | $114M | $115M | $97M | $100M | $97M | |
| SG&A Expense | $38M | $35M | $33M | $31M | $27M | $29M | $32M | $31M | $32M | $31M | $29M | $29M | $31M | $27M | $24M | $22M | |
| Operating Expenses | $120M | $116M | $122M | $125M | $124M | $137M | $149M | $154M | $146M | $143M | $138M | $143M | $146M | $125M | $124M | $119M | |
| Operating Income | $-113M | $-101M | $-99M | $-111M | $-110M | $-121M | $-136M | $-145M | $-139M | $-114M | $-140M | $-131M | $-132M | $-112M | $-110M | $-106M | |
| Interest Income | $6M | $5M | $6M | $7M | $7M | $9M | $11M | $12M | $12M | $13M | $12M | $13M | $13M | $12M | $5M | $2M | |
| Other Non-op | $6M | $4M | $3M | $10M | $9M | $6M | $8M | $9M | $-8M | $7M | $8M | $9M | $9M | $9M | $-3M | $-8M | |
| Net Income | $-107M | $-96M | $-96M | $-101M | $-101M | $-114M | $-129M | $-136M | $-147M | $-107M | $-132M | $-122M | $-124M | $-103M | $-113M | $-113M | |
| EPS (Basic) | $-0.80 | $-0.81 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.27 | $-1.34 | $-1.52 | $-1.12 | $-1.47 | $-1.38 | $-1.40 | $-1.17 | $-1.38 | $-1.49 | |
| EPS (Diluted) | $-0.80 | $-0.81 | $-0.81 | $-0.92 | $-0.98 | $-1.10 | $-1.27 | $-1.34 | $-1.52 | $-1.12 | $-1.47 | $-1.38 | $-1.40 | $-1.17 | $-1.38 | $-1.49 | |
| Shares (Basic) | 133,480,000 | 118,490,000 | -209,044,000 | 110,188,000 | 103,732,000 | 103,500,000 | -194,630,000 | 101,002,000 | 96,975,000 | 95,502,000 | -175,832,000 | 88,645,000 | 88,185,000 | 87,772,000 | -149,649,000 | 76,047,000 | |
| Shares (Diluted) | 133,480,000 | 118,490,000 | -209,044,000 | 110,188,000 | 103,732,000 | 103,500,000 | -194,630,000 | 101,002,000 | 96,975,000 | 95,502,000 | -175,832,000 | 88,645,000 | 88,185,000 | 87,772,000 | -149,649,000 | 76,047,000 | |
| EBITDA | $-111M | $-98M | · | $-109M | $-107M | $-118M | · | $-145M | $-139M | $-111M | · | $-131M | $-132M | $-110M | · | $-106M |
बैलेंस शीट 20
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $135M | $155M | $193M | $156M | $127M | $189M | $120M | $131M | $172M | $227M | $168M | $172M | $294M | $524M | $141M | |
| Short-term Investments | $332M | $241M | $294M | $318M | $303M | $377M | $412M | $538M | $560M | $619M | · | $687M | $736M | $639M | · | $687M | |
| Receivables | $7M | $9M | $9M | $11M | $11M | $11M | $9M | $9M | $12M | $36M | $36M | $6M | $5M | $5M | $4M | $4M | |
| Prepaid Expense | $83M | $81M | $68M | $60M | $25M | $37M | $30M | $44M | $54M | $56M | · | $32M | $26M | $25M | · | $27M | |
| Current Assets | $528M | $466M | $528M | $582M | $496M | $551M | $640M | $711M | $757M | $884M | · | $893M | $940M | $964M | · | $859M | |
| PP&E (Net) | $15M | $16M | $18M | $20M | $23M | $25M | $27M | $29M | $30M | $32M | · | $34M | $33M | $32M | · | $27M | |
| PP&E (Gross) | · | · | $76M | · | · | · | $77M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $59M | · | · | · | $50M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $857M | $759M | $842M | $925M | $899M | $986M | $1.19B | $1.17B | $1.19B | $1.26B | · | $1.24B | $1.32B | $1.42B | · | $1.08B | |
| Accounts Payable | $12M | $19M | $20M | $13M | $10M | $12M | $15M | $13M | $19M | $14M | · | $4M | $12M | $7M | · | $4M | |
| Accrued Liabilities | $44M | $38M | $50M | $41M | $42M | $41M | $55M | $51M | $45M | $43M | · | $58M | $50M | $45M | · | $58M | |
| Current Liabilities | $79M | $76M | $104M | $94M | $95M | $113M | $111M | $106M | $105M | $98M | · | $92M | $100M | $103M | · | $131M | |
| Capital Leases | $50M | $61M | $67M | $71M | $76M | $80M | $190M | $82M | $87M | $92M | · | $101M | $106M | $110M | · | $84M | |
| Total Liabilities | $129M | $138M | $171M | $177M | $184M | $206M | $319M | $211M | $220M | $223M | · | $206M | · | · | · | · | |
| Common Stock | $14.0K | $12.0K | $12.0K | $12.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | · | $9.0K | $9.0K | $9.0K | · | $8.0K | |
| Retained Earnings | $-2.79B | $-2.69B | $-2.59B | $-2.49B | $-2.39B | $-2.29B | $-2.18B | $-2.05B | $-1.91B | $-1.77B | · | $-1.53B | $-1.40B | $-1.28B | · | $-1.06B | |
| AOCI | $-1M | $-240.0K | $1M | $990.0K | $653.0K | $1M | $605.0K | $3M | $-1M | $-947.0K | · | $-4M | $-4M | $-3M | · | $-9M | |
| Stockholders' Equity | $728M | $621M | $671M | $748M | $715M | $780M | $872M | $963M | $971M | $1.04B | $1.05B | $1.04B | $1.10B | $1.19B | $1.24B | $825M | |
| Liabilities + Equity | $857M | $759M | $842M | $925M | $899M | $986M | $1.19B | $1.17B | $1.19B | $1.26B | · | $1.24B | $1.32B | $1.42B | · | $1.08B | |
| Shares Outstanding | 140,018,200 | 120,447,521 | 116,317,060 | 115,787,285 | 105,330,693 | 103,539,685 | 102,029,594 | 101,796,365 | 98,289,150 | 96,333,373 | 92,997,158 | 89,097,821 | 88,347,634 | 88,095,779 | 87,103,007 | 76,587,947 |
नकदी प्रवाह 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Stock-based Comp | $18M | $13M | $17M | $20M | $22M | $22M | $40M | $40M | $41M | $34M | $35M | $35M | $36M | $27M | $25M | $25M | |
| Restructuring | · | · | · | · | $6M | $6M | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-37M | · | · | · | $-59M | · | · | · | $-50M | · | · | · | $-36M | · | · | |
| Operating Cash Flow | $-83M | $-117M | $-69M | $-77M | $-100M | $-149M | $-85M | $-85M | $-58M | $-121M | $-93M | $-101M | $-90M | $-109M | $-90M | $-79M | |
| CapEx | $2M | $79.0K | $126.0K | $29.0K | $239.0K | $735.0K | $981.0K | $1M | $1M | $3M | $2M | $4M | $4M | $4M | $4M | $4M | |
| Investing Cash Flow | $-142M | $66M | $28M | $-741.0K | $107M | $94M | $152M | $-8M | $-24M | $6M | $46M | $80M | $-35M | $-122M | $-30M | $48M | |
| Financing Cash Flow | $196M | $34M | $2M | $115M | $15M | $0 | $2M | $82M | $41M | $60M | $106M | $19M | $3M | $2M | $506M | $24M | |
| Net Change in Cash | $-29M | $-17M | $-40M | $37M | $22M | $-55M | $69M | $-10M | $-41M | $-55M | $59M | $-3M | $-122M | $-229M | $386M | $-7M | |
| Free Cash Flow | · | $-117M | · | · | · | $-150M | · | · | · | $-123M | · | · | · | $-113M | · | · |
लाभप्रदता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1472.2% | -668.1% | · | -808.9% | -772.2% | -726.6% | · | -1589.0% | -1998.6% | -394.0% | · | -1093.3% | -973.5% | -888.1% | · | -795.5% | |
| Net Margin | -1392.3% | -639.5% | · | -735.2% | -710.8% | -687.6% | · | -1489.5% | -2112.6% | -371.3% | · | -1019.2% | -909.8% | -818.1% | · | -853.5% | |
| EBITDA Margin | -1444.8% | -653.4% | · | -791.5% | -754.6% | -711.5% | · | -1589.0% | -1998.6% | -385.3% | · | -1093.3% | -973.5% | -871.9% | · | -795.5% | |
| ROA | -12.1% | -11.0% | · | -9.7% | -9.7% | -10.2% | · | -11.2% | -11.7% | -8.0% | · | -10.5% | -10.2% | -7.9% | · | -9.4% | |
| ROE | -14.8% | -13.7% | · | -11.8% | -12.0% | -12.6% | · | -13.6% | -14.2% | -9.7% | · | -13.1% | -12.5% | -9.6% | · | -11.7% |
तरलता और शोधन क्षमता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | 6.1 | · | 6.2 | 5.2 | 4.9 | · | 6.7 | 7.2 | 9.0 | · | 9.7 | 9.4 | 9.3 | · | 6.6 | |
| Quick Ratio | 5.6 | 5.0 | · | 5.6 | 4.9 | 4.6 | · | 6.3 | 6.7 | 8.5 | · | 9.4 | 9.1 | 9.1 | · | 6.3 |
दक्षता 2
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 0.8 | 1.5 | · | 1.4 | 1.2 | 0.7 | · | 1.2 | 0.8 | 1.4 | · | 2.3 | 3.4 | 3.8 | · | 4.1 |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $51M | $60M | · | $54M | $47M | $62M | · | $57M | $61M | $67M | · | $51M | $53M | $51M | · | $46M | |
| Net Income TTM | $-405M | $-413M | · | $-453M | $-498M | $-504M | · | $-512M | $-500M | $-456M | · | $-462M | $-441M | $-464M | · | $-432M | |
| Market Cap | $2.37B | $1.54B | · | $2.00B | $988M | $736M | · | $2.09B | $2.20B | $2.65B | · | $2.82B | $3.60B | $3.28B | · | $4.29B | |
| P/E | -4.8 | -3.4 | · | -4.0 | -1.9 | -1.4 | · | -3.8 | -4.1 | -5.4 | · | -5.8 | -7.6 | -6.3 | · | -9.7 | |
| P/S | 46.7 | 25.9 | · | 37.2 | 21.0 | 11.9 | · | 36.7 | 35.8 | 39.5 | · | 54.7 | 67.3 | 64.2 | · | 93.7 | |
| P/B | 3.3 | 2.5 | · | 2.7 | 1.4 | 0.9 | · | 2.2 | 2.3 | 2.6 | · | 2.7 | 3.3 | 2.8 | · | 5.2 | |
| P / Tangible Book | 3.3 | 2.5 | · | 2.7 | 1.4 | 0.9 | · | 2.2 | 2.3 | 2.6 | · | 2.7 | 3.3 | 2.8 | · | 5.2 | |
| P / Cash Flow | · | -13.2 | · | · | · | -4.9 | · | · | · | -22.0 | · | · | · | -30.0 | · | · | |
| P / FCF | · | -13.2 | · | · | · | -4.9 | · | · | · | -21.5 | · | · | · | -29.0 | · | · | |
| Earnings Yield | -20.7% | -29.7% | · | -25.1% | -52.7% | -71.5% | · | -26.1% | -24.2% | -18.4% | · | -17.2% | -13.2% | -16.0% | · | -10.3% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $68M | $58M | $36M | $52M | $33M |
| परिचालन मार्जिन % | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% |
| शुद्ध आय | $-413M | $-519M | $-481M | $-474M | $-268M |
| तनुकरणित EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 5.1 | 5.8 | 8.7 | 9.6 | 6.1 |
| त्वरित अनुपात | 4.4 | 5.5 | 8.2 | 9.5 | 6.0 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-396M | $-355M | $-408M | $-347M | $-238M |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 373 फाइलर्स · $2.1B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 66 (+4 पिछली तिमाही की तुलना में) | 28 (-14 पिछली तिमाही की तुलना में) | 131 (+7 पिछली तिमाही की तुलना में) | 82 (+12 पिछली तिमाही की तुलना में) | +44.2M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| ARK Investment Management LLC | $285536575 | 16875684 | 13.62% | शेयर |
| STATE STREET CORP | $156255980 | 9234987 | 7.46% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $124064225 | 7332401 | 5.92% | शेयर |
| VANGUARD GROUP INC | $109190661 | 12145791 | 5.21% | शेयर |
| D. E. Shaw & Co., Inc. | $109021025 | 6443323 | 5.20% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $102003675 | 6028586 | 4.87% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $88582088 | 5235348 | 4.23% | शेयर |
| RA CAPITAL MANAGEMENT, L.P. | $76595588 | 4526926 | 3.65% | शेयर |
| FMR LLC | $69353456 | 4098904 | 3.31% | शेयर |
| REGENERON PHARMACEUTICALS, INC. | $62654675 | 3702995 | 2.99% | शेयर |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $55510459 | 3280760 | 2.65% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $52683658 | 3112991 | 2.51% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $49026191 | 2897529 | 2.34% | शेयर |
| Amova Asset Management Americas, Inc. | $49026191 | 2897529 | 2.34% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $41173682 | 2433433 | 1.96% | शेयर |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $34962744 | 2066356 | 1.67% | शेयर |
| Contrarius Group Holdings Ltd | $33082458 | 1955228 | 1.58% | शेयर |
| ARMISTICE CAPITAL, LLC | $25380000 | 1500000 | 1.21% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $23688068 | 1400004 | 1.13% | शेयर |
| GOLDMAN SACHS GROUP INC | $22647589 | 1338510 | 1.08% | शेयर |
| TWO SIGMA ADVISERS, LP | $21093390 | 2346317 | 1.01% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $20438362 | 1207941 | 0.98% | शेयर |
| Ghisallo Capital Management LLC | $20304000 | 1200000 | 0.97% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18227916 | 1077300 | 0.87% | कॉल ऑप्शन |
| Woodline Partners LP | $18194905 | 1075349 | 0.87% | शेयर |
| BAKER BROS. ADVISORS LP | $15739525 | 930232 | 0.75% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $15585367 | 921121 | 0.74% | शेयर |
| Connor, Clark & Lunn Investment Management Ltd. | $15210454 | 898963 | 0.73% | शेयर |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $13162880 | 777948 | 0.63% | शेयर |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $12284884 | 726057 | 0.59% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $10958729 | 647679 | 0.52% | शेयर |
| Marex Group Ltd | $10551312 | 623600 | 0.50% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $9776799 | 577825 | 0.47% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $9428010 | 557211 | 0.45% | शेयर |
| BlackRock, Inc. | $9138594 | 540106 | 0.44% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $8311544 | 491226 | 0.40% | शेयर |
| BANK OF AMERICA CORP /DE/ | $7682391 | 454042 | 0.37% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7267140 | 429500 | 0.35% | पुट ऑप्शन |
| Caption Management, LLC | $6757848 | 399400 | 0.32% | कॉल ऑप्शन |
| Point72 Asset Management, L.P. | $6741994 | 398463 | 0.32% | शेयर |
| Birchview Capital, LP | $6520968 | 385400 | 0.31% | शेयर |
| CITADEL ADVISORS LLC | $6321312 | 373600 | 0.30% | पुट ऑप्शन |
| Vestmark Advisory Solutions, Inc. | $6024028 | 356030 | 0.29% | शेयर |
| Casdin Capital, LLC | $6006600 | 355000 | 0.29% | शेयर |
| GFS Advisors, LLC | $5815143 | 130 | 0.28% | शेयर |
| FIRST TRUST ADVISORS LP | $5749534 | 339807 | 0.27% | शेयर |
| PINNACLE ASSOCIATES LTD | $5736286 | 339024 | 0.27% | शेयर |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $5531030 | 326893 | 0.26% | शेयर |
| CAPITAL FUND MANAGEMENT S.A. | $5048589 | 298380 | 0.24% | शेयर |
| Trexquant Investment LP | $5045104 | 298174 | 0.24% | शेयर |
| JANE STREET GROUP, LLC | $5030316 | 297300 | 0.24% | पुट ऑप्शन |
| JANE STREET GROUP, LLC | $4999860 | 295500 | 0.24% | कॉल ऑप्शन |
| UBS Group AG | $4967509 | 293588 | 0.24% | कॉल ऑप्शन |
| Swiss National Bank | $4350132 | 257100 | 0.21% | शेयर |
| CITADEL ADVISORS LLC | $4238460 | 250500 | 0.20% | कॉल ऑप्शन |
| Opaleye Management Inc. | $4230000 | 250000 | 0.20% | शेयर |
| AMERICAN CENTURY COMPANIES INC | $4044151 | 239016 | 0.19% | शेयर |
| CITIGROUP INC | $3814732 | 225457 | 0.18% | शेयर |
| DEUTSCHE BANK AG\ | $3562506 | 210550 | 0.17% | शेयर |
| Susquehanna Portfolio Strategies, LLC | $3544080 | 209461 | 0.17% | शेयर |
| XTX Topco Ltd | $3408297 | 201436 | 0.16% | शेयर |
| DIADEMA PARTNERS LP | $3384000 | 200000 | 0.16% | कॉल ऑप्शन |
| WASATCH ADVISORS LP | $3357096 | 261864 | 0.16% | शेयर |
| LPL Financial LLC | $3239842 | 191480 | 0.15% | शेयर |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $3226187 | 190673 | 0.15% | शेयर |
| ELEVATION POINT WEALTH PARTNERS, LLC | $3184463 | 188207 | 0.15% | शेयर |
| SECTOR GAMMA AS | $3133195 | 185177 | 0.15% | शेयर |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $3100844 | 183265 | 0.15% | शेयर |
| RHUMBLINE ADVISERS | $2990177 | 176725 | 0.14% | शेयर |
| UBS Group AG | $2881797 | 170319 | 0.14% | शेयर |
| CITADEL ADVISORS LLC | $2786927 | 164712 | 0.13% | शेयर |
| WOLVERINE TRADING, LLC | $2759652 | 163100 | 0.13% | कॉल ऑप्शन |
| Rafferty Asset Management, LLC | $2700111 | 159581 | 0.13% | शेयर |
| BLAIR WILLIAM & CO/IL | $2582195 | 152612 | 0.12% | शेयर |
| Bank of New York Mellon Corp | $2538795 | 150047 | 0.12% | शेयर |
| Point72 Asset Management, L.P. | $2431404 | 143700 | 0.12% | कॉल ऑप्शन |
| BARCLAYS PLC | $2430001 | 143617 | 0.12% | शेयर |
| MARSHALL WACE, LLP | $2377903 | 140538 | 0.11% | शेयर |
| Jefferies Financial Group Inc. | $2233440 | 132000 | 0.11% | कॉल ऑप्शन |
| WELLS FARGO & COMPANY/MN | $1991281 | 117688 | 0.10% | शेयर |
| TUDOR INVESTMENT CORP ET AL | $1978083 | 116908 | 0.09% | शेयर |
| GROUP ONE TRADING LLC | $1925970 | 113828 | 0.09% | शेयर |
| AMERIPRISE FINANCIAL INC | $1892012 | 111821 | 0.09% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $1837747 | 143350 | 0.09% | शेयर |
| OPPENHEIMER & CO INC | $1818105 | 107453 | 0.09% | शेयर |
| ENVESTNET ASSET MANAGEMENT INC | $1780170 | 105211 | 0.08% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1772480 | 138259 | 0.08% | शेयर |
| Cubist Systematic Strategies, LLC | $1762421 | 102051 | 0.08% | शेयर |
| Elmwood Wealth Management, Inc. | $1741813 | 102944 | 0.08% | शेयर |
| Deuterium Capital Management, LLC | $1692000 | 100000 | 0.08% | शेयर |
| MORGAN STANLEY | $1641240 | 97000 | 0.08% | शेयर |
| D.A. DAVIDSON & CO. | $1616537 | 95540 | 0.08% | शेयर |
| Headlands Technologies LLC | $1594710 | 94250 | 0.08% | शेयर |
| Havemeyer Place LP | $1522580 | 89987 | 0.07% | शेयर |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | $1493308 | 88257 | 0.07% | शेयर |
| VANGUARD ASSET MANAGEMENT, Ltd | $1486405 | 87849 | 0.07% | शेयर |
| Engineers Gate Manager LP | $1433598 | 84728 | 0.07% | शेयर |
| Caption Management, LLC | $1433124 | 84700 | 0.07% | शेयर |
| LAZARD ASSET MANAGEMENT LLC | $1427693 | 84379 | 0.07% | शेयर |
| JONES FINANCIAL COMPANIES LLLP | $1419835 | 85122 | 0.07% | शेयर |
कंपनी के अंदरूनी सूत्र 31 इनसाइडर्स · 17 अधिकारी · 16 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| John M. Leonard | President and CEO | 1 मार्च 2026 A | 1169739 | 0 | 4 | $-1150869 |
| Nessan Bermingham | President & CEO | 12 दिसमबर 2017 A | 458250 | 0 | 0 | $0 |
| Edward J Dulac III | EVP, Chief Financial Officer | 22 जुलाई 2026 S | 148175 | 0 | 3 | $-234186 |
| Glenn Goddard | EVP, Chief Financial Officer | 1 मार्च 2024 A | 69213 | 0 | 0 | $0 |
| Graeme Bell | EVP, Chief Financial Officer | 28 मार्च 2018 M | 21400 | 0 | 0 | $0 |
| Andrew Schiermeier | EVP, Chief Operating Officer | 3 मार्च 2021 A | 16656 | 0 | 0 | $0 |
| Dube Michael P | VP, Chief Accounting Officer | 1 जुलाई 2026 S | 66886 | 0 | 3 | $-104363 |
| Birgit C Schultes | EVP, Chief Scientific Officer | 1 मार्च 2026 A | 137733 | 0 | 2 | $-78898 |
| Eliana Clark | EVP, Chief Technical Officer | 1 मार्च 2026 A | 93864 | 0 | 2 | $-95997 |
| David Lebwohl | EVP, Chief Medical Officer | 1 मार्च 2026 A | 131192 | 0 | 1 | $-109627 |
| James Basta | EVP, General Counsel | 1 मार्च 2026 A | 156794 | 0 | 2 | $-112444 |
| Derek Hicks | EVP, Chief Business Officer | 3 जनवरी 2025 S | 59878 | 0 | 0 | $0 |
| Laura Sepp-Lorenzino | EVP, Chief Scientific Officer | 3 जनवरी 2025 S | 77388 | 0 | 0 | $0 |
| Jose E Rivera | EVP, General Counsel | 1 अप्रैल 2021 M | 162388 | 0 | 0 | $0 |
| Nicole Heifner | SVP, Accounting | 6 जनवरी 2017 A | — | 0 | 0 | $0 |
| David V Morrissey | SVP, Platform & Delivery Tech | 6 जनवरी 2017 A | — | 0 | 0 | $0 |
| Thomas M. Barnes | SVP, R&D eXtellia | 6 जनवरी 2017 A | — | 0 | 0 | $0 |
| Muna Bhanji | निदेशक | 9 जून 2026 A | 36403 | 0 | 0 | $0 |
| Georgia Keresty | निदेशक | 9 जून 2026 A | 41083 | 0 | 0 | $0 |
| Jesse Goodman | निदेशक | 9 जून 2026 A | 33559 | 0 | 0 | $0 |
| William J Chase | निदेशक | 9 जून 2026 A | 143893 | 1 | 0 | $1003000 |
| Brian Goff | निदेशक | 9 जून 2026 A | 32609 | 0 | 0 | $0 |
| Frank Verwiel | निदेशक | 9 जून 2026 A | 35148 | 0 | 0 | $0 |
| Fred Cohen | निदेशक | 9 जून 2026 A | 216653 | 1 | 0 | $1402500 |
| John F Crowley | निदेशक | 14 जून 2023 A | 11716 | 0 | 0 | $0 |
| Caroline Dorsa | निदेशक | 14 जून 2022 A | 12701 | 0 | 0 | $0 |
| FORMELA JEAN FRANCOIS | निदेशक | 14 जून 2022 A | 7291 | 0 | 0 | $0 |
| Perry A Karsen | निदेशक | 17 दिसमबर 2020 M | 5000 | 0 | 0 | $0 |
| Moncef Slaoui | निदेशक | 25 जुलाई 2017 A | — | 0 | 0 | $0 |
| GORDON CARL L | निदेशक | 18 मई 2017 A | 2662180 | 0 | 0 | $0 |
| Rachel E. Haurwitz | निदेशक | 11 मई 2016 C | 5593846 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 2 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Novartis Institutes for BioMedical Research, Inc., Novartis AG ×6 फाइलिंग | 22 जनवरी 2021 | — | प्रारंभिक फाइलिंग | — | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP V LLC, OrbiMed Global Healthcare GP LLC ×4 फाइलिंग | 16 फ़रवरी 2018 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 56 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| ARKG · ARK ETF Trust | 3.82% | 3498399 NS | 30 अप्रैल 2026 | N-PORT |
| ARKK · ARK ETF Trust | 2.06% | 9902541 NS | 30 अप्रैल 2026 | N-PORT |
| GNOM · Global X Funds | 1.59% | 63134 NS | 31 मई 2026 | N-PORT |
| BBC · ETFis Series Trust I | 1.10% | 30599 NS | 30 अप्रैल 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.56% | 215007 NS | 30 अप्रैल 2026 | N-PORT |
| IDNA · iShares Trust | 0.52% | 91888 SH | 8 अगस्त 2026 | दैनिक |
| HRTS · Tema ETF Trust | 0.38% | 13892 NS | 31 मई 2026 | N-PORT |
| FSCC · Federated Hermes ETF Trust | 0.24% | 47560 NS | 31 मई 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.23% | 182175 NS | 30 अप्रैल 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.15% | 117485 SH | 8 अगस्त 2026 | दैनिक |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.13% | 325592 SH | 8 अगस्त 2026 | दैनिक |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.12% | 108015 NS | 30 अप्रैल 2026 | N-PORT |
| IBB · iShares Trust | 0.11% | 970139 SH | 8 अगस्त 2026 | दैनिक |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.11% | 7603 SH | 8 अगस्त 2026 | दैनिक |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.10% | 201195 NS | 31 मई 2026 | N-PORT |
| IWN · iShares Trust | 0.10% | 1252101 SH | 8 अगस्त 2026 | दैनिक |
| GINN · Goldman Sachs ETF Trust | 0.10% | 14553 NS | 31 मई 2026 | N-PORT |
| BIB · ProShares Trust | 0.08% | 4369 NS | 31 मई 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.08% | 43955 NS | 30 अप्रैल 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 777703 SH | 8 अगस्त 2026 | दैनिक |
| VBK · VANGUARD INDEX FUNDS | 0.06% | 1798189 SH | 8 अगस्त 2026 | दैनिक |
| IWM · iShares Trust | 0.05% | 3453158 SH | 8 अगस्त 2026 | दैनिक |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.05% | 16989 NS | 30 अप्रैल 2026 | N-PORT |
| ISCV · iShares Trust | 0.05% | 29274 SH | 8 अगस्त 2026 | दैनिक |
| RSSL · Global X Funds | 0.05% | 48088 NS | 30 अप्रैल 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.04% | 10659 SH | 8 अगस्त 2026 | दैनिक |
| ITWO · ProShares Trust | 0.04% | 5225 NS | 31 मई 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0.04% | 633495 NS | 31 मई 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.04% | 385133 NS | 30 अप्रैल 2026 | N-PORT |
| TECB · iShares Trust | 0.03% | 13023 SH | 8 अगस्त 2026 | दैनिक |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 1604561 SH | 8 अगस्त 2026 | दैनिक |
| VB · VANGUARD INDEX FUNDS | 0.03% | 3110166 SH | 8 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.03% | 385422 SH | 8 अगस्त 2026 | दैनिक |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 50707 NS | 30 अप्रैल 2026 | N-PORT |
| UWM · ProShares Trust | 0.02% | 4087 NS | 31 मई 2026 | N-PORT |
| ISCB · iShares Trust | 0.02% | 5883 SH | 8 अगस्त 2026 | दैनिक |
| DXUV · Dimensional ETF Trust | 0.02% | 5693 NS | 30 अप्रैल 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0.02% | 12727 NS | 31 मई 2026 | N-PORT |
| URTY · ProShares Trust | 0.02% | 4136 NS | 31 मई 2026 | N-PORT |
| WSML · iShares Trust | 0.01% | 6761 SH | 8 अगस्त 2026 | दैनिक |
| DFAC · Dimensional ETF Trust | 0.01% | 319151 NS | 30 अप्रैल 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.01% | 70 NS | 31 मई 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.01% | 17865 NS | 30 अप्रैल 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.01% | 4295 NS | 31 मई 2026 | N-PORT |
| HDG · ProShares Trust | 0.01% | 104 NS | 31 मई 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0.01% | 40956 NS | 31 मई 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.00% | 6589 NS | 30 अप्रैल 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 32357 NS | 30 अप्रैल 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 37911 NS | 30 अप्रैल 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 197403 SH | 8 अगस्त 2026 | दैनिक |